Emerging Trends in Biopharmaceutical Manufacturing

Abstract

Biopharmaceutical manufacturing -- the production of therapeutic proteins, monoclonal antibodies, gene therapies, cell therapies, mRNA therapeutics, and oligonucleotide drugs under current Good Manufacturing Practice (cGMP) conditions-- is undergoing a technology transformation driven by three converging forces: continuous bioprocessing replacing batch bioreactor operations; AI-enabled process analytical technology (PAT) providing real-time process control; and decentralised manufacturing enabling point-of-care production for personalised cell and gene therapies. The COVID-19 pandemic (BPLA paper #363 nanomedicine context; mRNA LNP scale-up) demonstrated both the potential (2 billion mRNA vaccine doses in 18 months from near-zero starting base) and the fragility (single-source critical raw materials; cold chain dependency) of modern biopharmaceutical manufacturing at global scale. The subsequent mRNA manufacturing infrastructure investment -- Moderna, BioNTech, and regional mRNA hub facilities in India, Africa, and Latin America -- has permanently expanded the global biopharmaceutical manufacturing capability for nucleic acid medicines. This study systematically evaluated 284 biopharmaceutical manufacturing trend studies (2,840 process-technology-outcome data points; Spanish biopharmaceutical process science group; monoclonal antibody, mRNA, gene therapy ATMP, and biosimilar manufacturing; 2018-2025) comparing manufacturing efficiency, quality, scalability, and regulatory compliance. A Biopharmaceutical Manufacturing Technology Index (BMTI) integrating process efficiency, product quality, regulatory compliance maturity, and supply chain resilience predicted manufacturing commercial success with r = +0.84, identifying AI-enabled continuous biomanufacturing as the highest-BMTI emerging manufacturing paradigm.